DEPAKINE 200/MG/ML ORAL SOLUTION 40ML

Indications

Approved Uses

Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures

Dosage & Administration

Dosing by Condition

Epilepsy (adults): start ~10-15 mg/kg/day in divided doses and increase by ~5-10 mg/kg/week to usual 20-30 mg/kg/day (max 60 mg/kg/day). Epilepsy (children): similar weight-based initiation and titration; usual 20-30 mg/kg/day (max 60 mg/kg/day). Bipolar mania (adults): commonly start 750 mg/day (or ~20 mg/kg/day) in divided doses and titrate to clinical response (often 1000-2000 mg/day). Migraine prophylaxis (adults): typically 250 mg twice daily (or 500 mg/day) and titrate to 500-1000 mg/day as tolerated.

Initial Dose

Adults (epilepsy): 10-15 mg/kg/day PO in divided doses; titrate by 5-10 mg/kg/week. Adults (acute mania): 750 mg/day PO in divided doses (or 20 mg/kg/day) then adjust to clinical response/serum levels.

Maintenance Dose

Adults: 15-60 mg/kg/day PO in divided doses (commonly 1000-2000 mg/day). Pediatrics: 20-60 mg/kg/day PO in divided doses.

Maximum Dose

Maximum: 60 mg/kg/day PO (adults and pediatrics).

Children's Dosage

For epilepsy in children >10 years and >20kg, the typical starting dose is 10-15 mg/kg/day, with a maintenance dose of 20-30 mg/kg/day. Use with extreme caution and as a sole agent in children under 2 years.

Dose Adjustment Notes

Elderly: start at a lower dose and titrate more slowly; hepatic impairment: contraindicated in active liver disease/significant hepatic dysfunction; renal impairment: no routine dose adjustment, but consider lower doses and monitor clinical response/free (unbound) valproate as protein binding is reduced; titrate gradually to effect and tolerability.

How to Take

Oral use: measure the prescribed dose accurately with an oral syringe/measure; administer with or after food to reduce gastrointestinal upset; may be mixed with a small amount of water or non‑carbonated drink if needed; avoid mixing with carbonated beverages; do not stop abruptly.

How to Prepare

Ready-to-use oral solution (no reconstitution); measure the prescribed dose with an appropriate calibrated oral dosing device (e.g., oral syringe/medicine cup) and administer orally.

Side Effects

Common Side Effects

Nausea, vomiting, diarrhea, abdominal pain, tremor, weight gain, hair loss (alopecia), somnolence, dizziness, headache, thrombocytopenia, increased appetite

Side Effect Frequency

Very common (≥10%): nausea, tremor. Common (1-10%): vomiting, abdominal pain, diarrhea, somnolence/drowsiness, headache, weight gain, alopecia, thrombocytopenia. Serious reactions (rare/uncommon): hepatotoxicity/liver injury, pancreatitis, severe cutaneous reactions (e.g., SJS/TEN, DRESS), hyperammonemic encephalopathy.

Safety & Warnings

Contraindications

Contraindicated in: active liver disease/significant hepatic dysfunction; known mitochondrial disorders due to POLG mutations (and children <2 years suspected of POLG-related disease); urea cycle disorders; porphyria; hypersensitivity to valproate/valproic acid/sodium valproate. Pregnancy-related: contraindicated for migraine prophylaxis in pregnancy and in women of childbearing potential not using effective contraception/pregnancy-prevention program; for epilepsy, use in pregnancy only if no suitable alternative.

Warnings & Precautions

Key warnings/precautions: monitor for hepatotoxicity (baseline and frequent LFTs early in therapy, especially first 6 months) and pancreatitis; strict pregnancy prevention and avoidance in pregnancy unless no alternative (high teratogenic/neurodevelopmental risk); monitor for hyperammonemia/encephalopathy (higher risk with urea-cycle disorders or topiramate); monitor platelets/bleeding risk; monitor for suicidal ideation/behavior; counsel on weight gain/metabolic effects and other endocrine effects (e.g., menstrual/PCOS risk).

Age Restriction

No fixed minimum age restriction for epilepsy; can be used in children (including <10 years) when clinically indicated, but avoid if possible and use extreme caution in children <2 years (highest risk of fatal hepatotoxicity, especially with polytherapy or metabolic/mitochondrial disease).

Driving Warning

May Cause Drowsiness

Drug Interactions

Food Interaction

Take with or after food to improve gastrointestinal tolerability; food may slow absorption but does not meaningfully reduce overall exposure.

Special Populations

Pregnancy

Use only if other medications have failed to control epilepsy symptoms or are otherwise unacceptable (no traditional category; REMS program required)

Children

For epilepsy in children >10 years and >20kg, the typical starting dose is 10-15 mg/kg/day, with a maintenance dose of 20-30 mg/kg/day. Use with extreme caution and as a sole agent in children under 2 years.

Elderly

Start at lower doses and titrate slowly; elderly patients have reduced albumin levels leading to higher free drug concentrations; monitor closely for adverse effects and toxicity; reduce maintenance dose accordingly

Liver Impairment

Contraindicated in active liver disease or significant hepatic impairment; do not initiate/use in patients with significant hepatic dysfunction.

Storage & Patient Advice

Preparation Instructions

Ready-to-use oral solution (no reconstitution); measure the prescribed dose with an appropriate calibrated oral dosing device (e.g., oral syringe/medicine cup) and administer orally.

Missed Dose

Take the missed dose as soon as remembered; if it is close to the next scheduled dose, skip the missed dose and continue the regular schedule; do not double doses.

Stopping the Medicine

Do not stop abruptly; taper gradually under medical supervision to reduce risk of seizure exacerbation/status epilepticus.

Patient Counseling

Take exactly as prescribed and do not stop suddenly; take with/after food; measure doses accurately. Seek urgent care for signs of liver injury (jaundice, dark urine, severe fatigue, vomiting), pancreatitis (severe abdominal pain with nausea/vomiting), or unusual bruising/bleeding. May cause drowsiness-avoid driving until effects are known; avoid alcohol. High teratogenic risk: women of childbearing potential should use effective contraception and discuss pregnancy planning; attend scheduled blood tests/monitoring.

Monitoring Requirements

Baseline and periodic: liver function tests (especially during the first 6 months), full blood count including platelets; monitor weight/BMI; consider serum valproate concentration when assessing adherence, toxicity, interactions, pregnancy, or lack of response; check ammonia if unexplained lethargy/vomiting/encephalopathy; assess for pancreatitis if severe abdominal pain.

Pharmacology

Mechanism of Action

Increases brain GABA activity (including inhibition of GABA degradation), blocks voltage-gated sodium channels, and reduces T-type calcium currents, decreasing neuronal excitability.

Bioavailability

Oral bioavailability is high (generally ~90-100%); oral solution is rapidly and almost completely absorbed.

Metabolism

Extensively hepatic: mainly glucuronidation (UGT) and mitochondrial β-oxidation; minor CYP-mediated oxidation (e.g., CYP2C9/2C19).

Product Information

Available Dosage Forms

Oral solution, Gastro-resistant tablet, Modified-release tablet, Modified-release granules, Intravenous injection.

Composition per Dose

Each 1 ml: 200 mg valproate sodium

OTC Alternatives

No OTC alternative

Also Used For

Mood Stabilization, Migraine Prevention, Neuropathic Pain, Bipolar Disorder

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.